GlassScriptPhysician profile
Christopher Robert Kaiser
NPI 1497314785
$9,088.04
in general payments reported to CMS, 2019-2025
37 companies · $3,421 in 2025
The $3,421 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $747 · 2023: $1,795 · 2024: $2,786 · 2025: $3,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,716 · Education: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,715.99 |
| Education | $286.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,838.64 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $926.45 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Glaxosmithkline, LLC. | $921.07 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $605.47 | 2023-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $562.88 | 2021-2025 | |
| Genzyme Corporation | $547.99 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $362.08 | 2024-2025 | Zerbaxa, Keytruda, Recarbrio |
| United Therapeutics Corporation | $347.48 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $331.99 | 2022-2025 | Glassia |
| Insmed, INC. | $311.91 | 2022-2025 | Arikayce, Brinsupri |
| Amgen INC. | $299.84 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $225.01 | 2022-2024 | Yupelri |
| Axsome Therapeutics, INC. | $191.72 | 2023-2025 | Sunosi |
| Ani Pharmaceuticals, INC. | $156.74 | 2024-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $155.58 | 2023-2025 | Prolastin-C Liquid, Xembify |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $153.02 | 2023-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $143.70 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $142.22 | 2024-2025 | Lumryz |
| Baxter Healthcare | $138.28 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Viatris Specialty LLC | $111.84 | 2025 | Yupelri |
| Philips North America LLC | $71.89 | 2023-2024 | (Ak6) Vest Therapy |
| Teva Pharmaceuticals USA, INC. | $69.85 | 2022-2023 | Airduo Digihaler |
| Harmony Biosciences LLC | $67.00 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Genentech USA, INC. | $51.64 | 2023-2025 | Xolair |
| Mallinckrodt Hospital Products INC. | $41.42 | 2023 | Acthar |
| Vifor Pharma, INC. | $37.97 | 2024 | Zemaira |
| Lilly USA, LLC | $34.97 | 2025 | Zepbound |
| Inogen, INC. | $33.44 | 2024-2025 | |
| Stryker Corporation | $24.92 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inspire Medical Systems, INC. | $24.31 | 2025 | Inspire |
| Pfizer INC. | $23.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.17 | 2021 | |
| Almatica Pharma LLC | $15.82 | 2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $15.19 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $13.98 | 2025 | Nuzyra |
| Ethicon INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.